Trial Profile

A Phase 2b Randomized, Double-blind, Placebo-controlled, Multicenter Dose Ranging Study to Evaluate Efficacy and Safety of CD388, a Novel Long-acting Antiviral Conjugate, for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 30 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CD 388 (Primary)
Indications Influenza A virus infections; Influenza B virus infections; Influenza virus infections
Focus Adverse reactions; Therapeutic Use
Acronyms NAVIGATE
Sponsors Cidara Therapeutics

23 Oct 2025 According to a Cidara Therapeutics media release, company presented data from this study at the European Scientific Working Group on Influenza (ESWI) 10th Influenza Conference taking place October 20-23, 2025 in Valencia, Spain.
23 Oct 2025 Results published in the Cidara Therapeutics media release.
21 Oct 2025 According to a Cidara Therapeutics media release, data from this trial presented during ID Week 2025

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com